​
​

Carmell Therapeutics Stock (NASDAQ:CTCX)

RevenueOwnershipFinancialsChart
Carmell Therapeutics by TradingView

Previous Close

$0.25

52W Range

$0.20 - $4.31

50D Avg

$0.37

200D Avg

$1.62

Market Cap

$5.21M

Avg Vol (3M)

$4.76M

Beta

0.31

Div Yield

-

CTCX Company Profile

Carmell Therapeutics Corporation focuses on the development of plasma-based bioactive material (PBM) to stimulate tissue repair or growth after injury, disease, and aging. Its lead product candidate is CT-101 bone healing accelerant for tibia fracture healing, foot/ankle fusion, spinal fusion, dental bone graft substitute, and bone void filler; and tissue healing accelerant for androgenetic alopecia and chronic wound healing. The company was founded in 2008 and is based in Pittsburgh, Pennsylvania.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

9

IPO Date

Sep 23, 2021

Website

CTCX Performance

CTCX Financial Summary

Dec 23Dec 22Dec 21
Revenue---
Operating Income$-5.22M$-5.51M$-1.94M
Net Income$-15.45M$-9.05M$-6.48M
EBITDA$-5.09M$-5.25M$-1.66M
Basic EPS$-1.40$-0.46$-0.33
Diluted EPS$-1.40$-0.46$-0.33

Fiscal year ends in Dec 23 | Currency in USD